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Copyright © 200? JCBN Summary Two vitamins and proline (CB6Pro), three nutrients essential for bone collagen,
were used in combination to a 1000 mg calcium/250 IU vitamin D (Ca/D) daily supplement to
treat osteopenia as a preventive measure against osteoporosis later in life. Middle-aged women
not using estrogen were screened for osteopenia using the WHO criteria and divided into three
groups (n = 20 each): 1) placebo healthy controls with normal bone mineral density (BMD);
2) control Ca/D-treated osteopenic patients; and 3) Ca/D + CB6Pro-treated osteopenic patients.
The three groups were comparable at baseline except for BMD. After one-year treatment, cor-
tical diaphyseal BMD remained constant in each group, but trabecular bone loss persisted (at
5 lumbar sites) in osteopenic group 2. No further bone loss was detected in osteopenic group
3. A loss of 2% was evidenced in the placebo group at one lumbar site. Markers of bone for-
mation (which increase in coupling to resorption) decreased significantly in both osteopenic
groups. Although biomarkers of resorption did not change, hormone (PTH and 1,25(OH)2D3)-
induced osteoclastic activity was significantly reduced. No decline in BMD occurred at any
bone site in osteopenic group 3, highlighting the importance of improving the quality of bone
matrix concomitantly to mineral replacement.
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Introduction
A slow decline begins to occur after peak bone mass has
been reached. Baran [1] suggested that the loss of bone mass
starts at about age 35 in women. According to Garton et al.
[2], ovulatory changes that amplify as women progress
through perimenopause are associated with bone loss despite
normal serum estradiol levels and regular menstrual cycles.
A relatively modest but significant amount of cancellous
bone, especially in the vertebral bodies and femur Ward’s
triangle, is lost within 10 years preceding menopause,
whereas cortical bone mass is maintained until menopause
[3].
Women account for more than two out of three cases of
osteoporosis. They are particularly at risk due to high
nutritional demand for calcium during pregnancy and lacta-
tion [4]. To our knowledge, no nutrient supplemental inter-
vention attempts have been made to prevent further bone
loss in middle-aged eumenorrheic women, at risk of fractureTreating Osteopenia with Key Nutrients to Bone Collagen
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due to diagnosed low bone mass (but otherwise healthy).
This is despite the fact that it is now firmly established that
low bone mass (osteopenia) is a significant risk factor for
osteoporotic fractures later in life [5]. Reduced bone mass
results from an imbalance in the bone-remodeling unit as a
function of enhanced bone turnover without a commensurate
increase in bone formation [6].
Calcium supplementation is the leading nutritional inter-
vention for osteoporosis treatment and prevention. Other
nutrients have received far less attention. Controversy
prevails in regard to calcium although several studies have
addressed the effects of this mineral on bone density and
turnover, particularly in postmenopausal women [7–10].
According to Fardellone et al. [7], two months of calcium
supplementation was efficient in reducing biomarkers of
bone turnover in postmenopausal women, with a greater
effect in women with a low dietary intake. It would take a
much longer time to observe a change in bone mineral
density (BMD) because the bone-remodeling cycle ranges
from 30 to 80 weeks according to Heaney’s simulation
model [6]. This investigator referred to a reference mineral-
ization period of 40 weeks. On the basis of highly reliable
static and tetracycline-based (dynamic) histomorphometric
data on humans, the average length of time required to com-
plete the remodeling cycle is approximately 6 months [11].
Bone matrix is a complex, highly mineralized tissue with
a structural framework composed primarily of collagen [12].
Several nutritional factors other than calcium are involved,
but their influence on BMD and biomarkers of bone turn-
over, particularly the new one (type I collagen helical
peptide), is still largely unknown. An early correlation study
showed that several nutrients were related to bone loss in
women (aged between 35–65 years) [13]. Vitamins C
(ascorbic acid) and B6 are vital components in the biology of
bone cells and resultant bone mass. Vitamin C is the required
coenzyme in the hydroxylation of proline and lysine during
collagen synthesis in osteoblasts (bone cells) whereas
vitamin B6 is involved as coenzyme in the assembly process
of collagen (aldehyde cross-link formation) in the extra-
cellular matrix. Masse et al.’s biomechanical study demon-
strated the importance of this extracellular process for the
strength of bone using a vitamin B6-deficient animal model
[14]. The only clinical study on this vitamin in relation to
bone was reported by Reynolds et al. [15] who showed that
half of their hip fracture patients were vitamin B6-deficient.
Administering to healthy postmenopausal women, either
calcium alone (1450 mg) or with a multivitamin/mineral
preparation containing small doses of vitamins C and B6
(120 mg and 2 mg, respectively), Jensen et al. [16] obtained
significant reductions of parathyroid hormone (PTH) and
pyridinium collagen cross-links after one-year supplementa-
tion. This multivitamin preparation succeeded in reducing
bone loss in contrast to calcium taken alone. Morton et al.’s
[17] postmenopausal women taking vitamin C in pharmaco-
logical dose (745 mg in average) had significantly higher
BMD at all sites, but they were on hormone (estrogen)
replacement therapy. According to Leveille et al. [18], long
term use of vitamin C supplement was associated with a
higher BMD in the early postmenopausal years (when bone
loss is the most rapid) and among never users of estrogen.
Studies on vitamin C in relation to bone are limited and
showed inconsistent results. Results from the PEPI study
indicated that the positive association between vitamin C
and BMD is modified by the level of dietary calcium intake,
with diets high in calcium enhancing the association [19]. To
our knowledge, there are no well-controlled studies on the
effects of pharmacological doses of vitamin B6, and proline
as well, in relation to bone health status. Proline is a very
specific amino acid in the sequence of the three collagen
polypeptide chains and is also essential for the molecular
stability of this triple helical molecular structure.
The present follow-up study on middle-aged osteopenic
patients was aimed to treat their bone loss using a nutritive
preparation containing three nutrients essential in collagen
formation, administered in pharmacologic doses for one-year,
in conjunction with a conventional calcium/vitamin D
supplement, as an early preventive measure against osteo-
porosis. This new approach is based on the hypothesis that
improvement and stabilization of the collagenous bone
matrix structure will enhance the efficacy of calcium/vitamin




Female volunteers, aged between 35 and 55 year-old and
non-estrogen users, were recruited during a mid-spring/
summer to enrol in a one-year nutritional intervention
project on osteopenia in middle age. Over 150 women from
a homogenous Caucasian population living in the same
Eastern Canada urban area (latitude 46° North) responded to
various public advertisements in which all other selection
criteria were clearly specified: non-smoker, eating a normal
mixed (non-vegetarian) diet, non obese (BMI<30 kg/m2)
and in good health (as self-assessed) without history of bone
fracture [20], hysterectomy and no regular use of medication
or vitamin/calcium supplements. These specific criteria
were aimed to recruit a biologically homogeneous popula-
tion sample and to avoid factors susceptible to modify
bone metabolism and density. An initial screening of all
respondents was conducted over the phone to exclude non-
eligible subjects.
Women who met the inclusion criteria attended the initial
information meeting and signed a consent form. They were
assigned a number to keep their anonymity and filled out aP.G. Masse et al.
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general questionnaire, which included items on socioecom-
omic background, reproductive characteristics, personal and
family medical history. The research protocol was approved
by the Ethics Committee on Human Research of the Univer-
sité de Moncton and by the Review Board of Dumont
Hospital, Moncton, NB, Canada.
Dual energy X-ray absorptiometry (DEXA, Lunar Corp.,
Madison, WI) and the well-established WHO criteria [21]
were used for the screening of osteopenia. It is defined as a
value of BMD between 1.0 and 2.5 SD below the average
value (T-score) of the peak bone mass of healthy 30 year-old
adults. Women with normal BMD served as healthy placebo
controls (n = 20). Osteopenic patients were treated either
with a conventional calcium supplement containing vitamin
D (OsCalD®, Wyeth-Ayerst Canada, Montréal, Canada) or
with OsCalD® plus CB6Pro, a nutritive capsule containing
500 mg ascorbic acid (vitamin C), 75 mg pyridoxine hydro-
chloride (vitamin B6) and 500 mg proline. This capsule,
prepared by Peter Ford Apothecary Laboratory (Moncton,
Canada), was taken orally once a day with breakfast. The
OsCalD® tablets were taken twice daily, at breakfast and
bedtime. Each tablet contained 500 mg calcium carbonate
and 125 IU vitamin D. A full-year supply of placebo,
calcium/vitamin D tablets, and CB6Pro capsules were
double-blind (to main investigator and subjects) provided
to each subject by the pharmacist.
Evaluation of bone mineral density (BMD)
BMD of the lumbar spine (L1 to L4 and Li-Lj [i =1  t o  3 ;
j = i + 1 to 4]) and femoral sites (neck, Ward’s triangle,
trochanter and diaphysis) were evaluated at the beginning
and at the end of the study. All scans were performed and
analysed by the same experienced technician. The bone
densitometer was calibrated on a daily basis according to the
manufacturer’s instructions. Reproducibility was calculated
as a coefficient of variation (CV) obtained by weekly mea-
surements of a standard aluminium bar phantom on the
instrument and in vivo by repeated measurements (5 times)
obtained in three patients of different ages. The CV of the
instrument was 0.5% with the standard phantom; in vivo,
the CV was calculated to be 1.1% for the lumbar spine, 1.5%
for the neck of femur, 3.2% for Ward’s triangle, 1.8% for
trochanter and 1.0% for diaphysis. For the diaphyseal
measurements, the upper shaft of the proximal femur was
scanned below the intertrochanteric line.
Anthropometric measurements
Subjects were weighed and measured for height. Their
body mass index (BMI) was calculated from measured
weight (kg) and height (m) as weight/(height)2. Body frame
size was assessed by the elbow width method (cm) according
to Frisancho and Flegel [22]. Waist and hip circumferences
(cm) where used to calculate the waist-to-hip ratio, an indi-
cator of body fat distribution [23]. Adipose tissue mass (%)
was estimated from skinfold thickness using the prediction
equation of Durnin and Womersley [24]. Skinfold thickness
was measured in triplicate to the nearest 0.5 mm with a
constant-pressure Harpenden skinfold caliper, at three
different sites of the left side of the body: 1) triceps, halfway
between the acromion and the olecranon; 2) subscapular,
about 20 mm below the tip of the scapula, at an angle of 45°
to the lateral side of the body; and 3) supra-iliac, about
20 mm above the iliac crest, in the axillary line.
Evaluation of self-selected diets
Subjects were asked at the beginning of the study to
record their food intakes for 3 non-consecutive days
(including one week-end day) preceding the first blood
collection. Written instructions were given to all of them
and explained by a registered dietitian to maximize com-
pleteness and accuracy of recording. Subjects were asked
not to modify their regular food intakes while recording and
to record all foods and beverages immediately after con-
sumption. Dietary records were checked for completeness
by the same dietitian in the presence of the subjects when
they met individually for a second time. Daily energy and
nutrient intakes, including proline and lysine, were deter-
mined using Food Processor® (Version 8.2, 2000, Esha
Research, Salem, OR). Energy and nutrient intakes were
averaged (n = 3 days) to compare the three subject groups
prior to the intervention and to assess the nutritional ade-
quacy of their diets with respect to current nutrition stan-
dards [25]. Ca: P and P: protein ratios were calculated.
Biochemical analyses
In the morning, after an overnight fast, antecubital venous
blood and urine samples were collected twice, the same day
as bone densitometry, before and after the nutritional inter-
vention. All samples were kept frozen at −70°C until the end
of the study to analyze pre- and post-treatment samples in
parallel. Ten-mL Vacutainer® tubes were used for collecting
blood sample to assay the concentrations of serum estradiol,
calcium, inorganic phosphorus and intact (i) PTH. Blood
was allowed to clot for 1h at 37°C and centrifuged at
2000 × g for 10 min at 4°C. An enzyme immunoassay
(Abbott IMx®, Abbott Laboratories, Chicago, IL) was used
for the analytical determination of serum estradiol. Serum
iPTH, calcium and inorganic phosphorus were determined
by automated routine procedures.
Two other blood samples, withdrawn in a 5 mL tube con-
taining either heparin or EDTA (depending on the analysis),
were centrifuged within 15 min at low speed (2000 × g for
10 min) to obtain the plasma. Plasma bone turnover markers
were analysed in a laboratory of the Palo Alto VA Medical
Center, CA, by methods that were validated and reported
previously [26, 27]. Markers of bone resorption were mea-Treating Osteopenia with Key Nutrients to Bone Collagen
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sured on nonhydrolyzed urine samples using a competitive
enzyme immunoassay for free deoxypyridinoline (fDpd)
(Metra DPD, Quidel Corporation, Mountain View, CA) and
the most recent marker, type I collagen helical peptide
(Metra Helical, Quidel Corporation). Both measurements
were corrected for the urinary concentration of creatinine
(Cr), which was determined using a colorimetric technique
based on Metra assay kit (Quidel Corporation). Plasma
osteocalcin (OC) and bone specific alkaline phosphatase
(bALP) were measured with a 2-site immunoradiometric
assay kit (Diagnostic Systems Laboratories, Webster, TX)
and with a monoclonal antibody that demonstrates speci-
ficity for bALP using Tandem R Ostase Beckman Coulter
kit (Fullertown, CA), respectively. Plasma calcitriol
[1,25(OH)2D3] concentration was measured using a radio-
immunoassay from Nichols Institute Diagnostics (San Juan
Capistrano, CA).
Plasma pyridoxal’5-phosphate (PLP), active coenzyme
form of vitamin B6, and its end metabolite in urine (4-
pyridoxic acid, 4-PA), were determined using cation ex-
change HPLC [28]. These two metabolites were used to
assess the vitamin B6 nutritional status and the compliance
with the CB6Pro prescription, respectively. Urinary 4-PA
was expressed as mmol per mmol creatinine. Plasma con-
centration of calcidiol [25(OH)D3], hepatic precursor of
1,25(OH)2D3, which was used as an indicator of vitamin D
nutritional status, was determined following extraction of
serum in reagent alcohol (90% ethanol, 5% methanol, 5%
isopropanol) with a competitive protein-binding assay kit
(Nichols Institute Diagnostics). The intra-assay CV for all
assays was less than 8%.
Statistical analyses
GraphPadInstat® (Version 2.0, 1998, GraphPad Software,
San Diego, CA) was used for statistical analysis. Data are
reported as means ± standard deviation (SD), except where
indicated. Data were first analysed to verify for Gaussian
distribution and equality of variance. One-way analysis of
variance (ANOVA) followed by Bonferroni post-hoc test
was used to test the significance of differences between
mean values obtained from the evaluation of the three subject
groups at baseline. The effect of each treatment (placebo,
calcium/vitamin D and calcium/vitamin D + CB6Pro) was
analysed by a two-tailed paired Student’s t test. Values of
p≤0.05 were considered significant.
Results
The three groups were comparable at baseline in several
aspects, namely, socio-economic background (not shown),
age, body weight and frame, height, BMI, serum estradiol,
biochemical markers of calcium and bone metabolism, and
vitamins B6 and D nutritional status as assessed by plasma
PLP and 25(OH)D3, respectively (Table 1). They were also
comparable in terms of dietary intakes, including proline and
lysine, amino acids essential for collagen synthesis and its
structural stability in bone matrix (Table 2). Body weight
was normal in each group. Dietary intakes of proteins,
vitamins and minerals involved in bone metabolism, were
adequate, except for vitamin D, magnesium, copper and zinc
for the three groups. Their calcium intakes almost reached
the newly established high requirement of 1000 mg. Vitamins
C and B6 were above the current nutritional recommenda-
tions. Subjects were not B6- or D-deficient as judged by
plasma PLP and 25(OH)D3 levels within normal ranges,
respectively (Table 1). The calcium/vitamin D + CB6Pro-
treated osteopenic group complied with the CB6Pro pre-
scription as judged by the significant (p<0.01) 12-fold eleva-
tion of urinary 4-PA excretion at the end of the one-year
treatment (Fig. 1). No side effects were observed throughout
Table 1. Baseline basic characteristics of each subject group (n = 20)
Means ± SD, except where indicated. BMD, bone mineral density; BMI, body mass index; PLP, pyridoxal’5-phosphate. None
of the differences between groups were significant. § 95% confidence interval.
Normal BMD control group Osteopenic groups
Placebo Calcium/Vit. D Calcium/Vit. D + CB6Pro
Age (years) 44.6 ± 6.9 49.0 ± 5.6 47.9 ± 7.7
Weight (kg) 69.8 ± 11.7 68.3 ± 9.3 63.8 ± 9.1
Height (m) 1.60 ± 0.05 1.59 ± 0.06 1.60 ± 0.08
BMI (kg/m2) 27.2 ± 3.9 26.9 ± 3.2 24.9 ± 3.5
Elbow width (cm) 6.45 ± 0.61 6.47 ± 0.53 6.28 ± 0.4
Waist hip ratio (cm/cm) 0.78 ± 0.08 0.78 ± 0.06 0.78 ± 0.07
Body fat (%) 35.8 ± 5.2 38.4 ± 5.3 37.5 ± 6.5
Serum estradiol (pmol/L) 236 – 767§ 164 – 556§ 178 – 503§
Plasma PLP (nmol/L) 31.01 – 41.77§ 27.77 – 69.12§ 30.02 – 59.41§
Plasma 25(OH)D3 (nmol/L) 81.35 ± 46.30 72.72 ± 18.65 72.25 ± 33.82P.G. Masse et al.
J. Clin. Biochem. Nutr.
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the study period in any of the groups and no subjects
dropped out.
Table 3 summarizes the effect of the calcium/vitamin
D+C B 6Pro treatment on bone metabolism and turnover in
comparison to control osteopenic group and healthy normal
controls having received a calcium/vitamin D supplement
alone and a placebo, respectively. No biochemical change
was observed in the healthy controls on placebo. Both
markers of bone formation (bALP and OC, which increase
in osteopenia secondarily to resorption) were significantly
lowered in both osteopenic groups (Table 3). Although no
reduction of resorption was evidenced biochemically (fDpd
Table 2. Daily pertinent nutrient intakes for each subject group (n = 20)
Means ± SD. BMD, bone mineral density; DRI, dietary reference intakes; RAE, retinol activity equivalents. None of the differences
between groups were significant. a From the Institute of Medicine (2000) [25].
Normal BMD control group Osteopenic groups
DRIa Placebo Calcium/Vit. D Calcium/Vit. D + CB6Pro
Energy (kcal) — 2002 ± 740 1880 ± 611 1815 ± 428
Proteins (g) 50 84.0 ± 20.6 80.4 ± 31.4 68.5 ± 16.7
Proline (g) — 3.9 ± 0.9 3.3 ± 1.1 3.1 ± 1.0
Lysine (g) — 5.0 ± 1.4 4.2 ± 1.4 4.0 ± 1.2
Ca (mg) 1000 952 ± 357 920 ± 220 914 ± 223
P (mg) 700 1409 ± 348 1463 ± 681 1338 ± 267
Ca:P (mg/mg) — 0.70 ± 0.14 0.70 ± 0.27 0.70 ± 0.14
P:proteins (mg/g) — 16.90 ± 2.28 17.20 ± 3.48 18.60 ± 3.03
Mn (mg) 2 2.3 ± 0.8 2.3 ± 1.0 2.3 ± 1.0
Mg (mg) 320 269 ± 81 260 ± 93 260 ± 90
Cu (μg) 2 1.3 ± 0.4 1.2 ± 0.3 1.3 ± 0.5
Zn (mg) 12 9.7 ± 3.2 9.3 ± 4.5 9.1 ± 1.5
Vit C (mg) 60 105 ± 50 104 ± 33 102 ± 32
Vit A (μg RAE) 800 1192 ± 841 1167 ± 457 1188 ± 323
Vit B6 (mg) 1.3 1.9 ± 0.4 1.7 ± 0.6 1.6 ± 0.6
Vit D (μg) 5 3.6 ± 1.2 2.4 ± 1.6 2.1 ± 1.3
Fig. 1. Compliance of the calcium/vitamin D + CB6Pro-treated osteopenic group (n = 20) to the nutritive prescription (CB6Pro), as
assessed by urinary excretion of pyridoxic acid (4-PA), vitamin B6 end-metabolite. Plain and hatched dark grey bars, respectively,
represent pre- and post-treatment values. Pre- and post-treatment values of 4-PA are also shown for the normal controls
receiving a placebo and the control osteopenic group treated with calcium/vitamin D (white and light grey bars, respectively)
(n = 20 per group). Data are means ± SD. Asterisks indicate the significance level for pre- and post-treatment comparison for
the experimental osteopenic group: **p<0.01. There was no significant difference for the normal and osteopenic control groups
not receiving vitamin B6 (CB6Pro) as expected.Treating Osteopenia with Key Nutrients to Bone Collagen
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and helical peptide) at the end of the one year-treatment,
osteoclastic activity, as assessed by two major calciotropic
hormones, was significantly reduced in both osteopenic
groups. The 13 and 25% reductions of iPTH were significant
in both groups. Like PTH, 1,25(OH)2D3 seemed to be more
sensitive to calcium/vitamin D administered alone (control
osteopenic group). 1,25(OH)2D3 decreased by 20% (p<0.05)
in this group. The 17% reduction in the calcium/vitamin
D+C B 6Pro-treated osteopenic group almost reached a
significant level (p = 0.06). The concentration of 25(OH)D3
did not change regardless of group.
BMD in the healthy control group having received a
placebo did not change after one year, except that a signifi-
cant 2% loss (p<0.05) at L1-L2 site occurred (Fig. 2B).
Osteopenic patients treated with the conventional calcium/
vitamin D supplement continued to lose bone minerals, to a
much greater extent than the normal BMD controls, as
shown by significant reductions in BMD at five lumbar sites
(L3, L1-L2, L1-L3, L1-L4, L2-L3; significance levels
indicated on Fig. 2A and B) at the end of the study. However,
the femur neck BMD was significantly improved (p<0.05)
(Fig. 2C). The combination of calcium/vitamin D with the
three key collagen-related nutrients (vitamins C and B6 +
proline) administered to osteopenic group 3 deterred further
bone loss at all bone sites, at least during the one-year treat-
ment period, compared to the results obtained in the two
other groups, especially the other osteopenic group treated
with calcium/vitamin D alone. Cortical diaphyseal bone
remained constant in each group during the study.
Discussion
The occurrence of bone loss in mid-age when serum
estradiol levels are within normal range can indicate either
that maximum peak bone mass was not achieved, or the
beginning of a decline in new bone formation not matching
the normal resorption rate. The first event is very difficult to
demonstrate without a long-term longitudinal study starting
during adolescence. The second event may be influenced by
the quality of the collagenous matrix, as suggested by funda-
mental research data from our vitaminB6-deficient animal
model [14]. The present study showed the effect of a nutri-
tional intervention targeting both major bone components
(collagen matrix and minerals) for treating osteopenia in
middle-aged menstruating women. It provided evidence that
treating bone loss as a resorptive problem that commands
calcium restoration with no attempt to improve bone matrix
is not optimal.
Nutritional vitamin B6 status of the three subject groups
was considered adequate based on the cut-off of 20 nmol/L
[29]. Nutritional vitamin C status could not be assessed
biochemically due to the unavailability of the technique in
our laboratory at the time of the study. However, by extra-
polating from the dietary intake values which were almost
2-fold the recommendation, nutritional status inadequacy
seemed unlikely. Low plasma 25(OH)D3 concentration can
lead to osteopenia [30]. Our three subject groups had
adequate vitamin D status as assessed by this biochemical
indicator (cut-off level established at 50 nmol/L [31])
despite insufficient dietary intakes. Dietetic evaluation,
which only provides an estimate of total vitamin D intake
from natural sources and fortified foods, does not take into
consideration endogenous photosynthesis of vitamin D in
the skin under influence of sunlight (or artificial ultraviolet
radiation). Accurate dietary estimates of vitamin D intakes
are not available, in part because the vitamin D composition
of fortified foods is highly variable [32]. Using food com-
position data from the second National Health and Nutrition
Examination Survey (NHANES II), a median vitamin D
intake of 2.3 μg (90 IU) per day, was estimated for adult
women. The level proposed as adequate plasma 25(OH)D3
concentration to prevent compensatory hypersecretion of
Table 3. Pre- and post-treatment biochemical indices of bone metabolism and turnover in each subject group (n = 20)
Means ± SD. bALP, bone alkaline phosphatase; BMD, bone mineral density; Cr, creatinine; fDpd, free deoxypyridinoline; iPTH, intact
parathyroid hormone; Pi, inorganic phosphorus. *p<0.05 Pre vs Post. **p<0.01 Pre vs Post. ***p<0.001 Pre vs Post.
Normal BMD control group Calcium/Vit. D osteopenic group Calcium/Vit. D + CB6Pro osteopenic group
Pre Post Pre Post Pre Post
Ca (mmol/L) 2.32 ± 0.11 2.33 ± 0.09 2.29 ± 0.08 2.30 ± 0.08 2.37 ± 0.13 2.33 ± 0.08
Pi (mmol/L) 1.05 ± 0.15 1.06 ± 0.12 1.06 ± 0.14 1.06 ± 0.14 1.05 ± 0.13 1.08 ± 0.13
bALP (µg/L) 6.13 ± 3.56 6.39 ± 3.18 7.49 ± 3.09 5.73 ± 2.63*** 6.95 ± 2.58 5.11 ± 2.01***
Osteocalcin (ng/mL) 37.14 ± 8.39 36.18 ± 11.72 39.34 ± 8.25 33.65 ± 11.67*** 44.36 ± 5.60 40.44 ± 5.92**
Helical peptide (µg/mmol Cr) 44.68 ± 28.98 40.05 ± 25.82 46.74 ± 21.16 43.24 ± 32.86 53.49 ± 23.42 48.65 ± 22.92
fDpd (nmol/mmol Cr) 4.42 ± 1.39 4.62 ± 1.24 4.97 ± 2.11 4.43 ± 1.82 4.69 ± 1.54 4.36 ± 1.29
iPTH (pmol/L) 2.99 ± 1.51 3.12 ± 1.20 3.83 ± 1.47 2.85 ± 1.22*** 2.95 ± 0.92 2.56 ± 0.73*
25(OH)D3 (nmol/L) 81.35 ± 46.30 90.52 ± 54.52 72.72 ± 18.65 79.00 ± 36.00 75.25 ± 33.82 81.25 ± 31.67
1,25(OH)2D3 (pmol/L) 0.63 ± 0.33 0.69 ± 0.24 0.83 ± 0.35 0.66 ± 0.32* 0.71 ± 0.25 0.59 ± 0.20P.G. Masse et al.
J. Clin. Biochem. Nutr.
26
PTH varies from 62 to 100 nmol/L [16,  27]. The mean
plasma concentration of this vitamin was within this range
for the three subject groups in the present study. The total
daily dose of 250 IU provided by two tablets of OsCalD to
osteopenic patients was insufficient to increase their plasma
25(OH)D3 concentration. According to Dawson-Hugues et al.
[33], an increase from 5.0 μg (200 IU) to 20 μg (800 IU)
caused an increment of only 8 nmol/L in postmenopausal
women. It is a different case in older women because they
are likely to be vitamin D-deficient. For instance, Ooms
et al. [34] obtained an elevation of 35 nmol/L for elderly
women when using 400 IU.
In the present study, both bALP and OC (which increase
in coupling to bone resorption) were significantly reduced in
both treated osteopenic groups, probably as a consequence
of the inhibition of bone resorption. bALP is known to be
the most sensitive biomarker to treatment [35]. In effect, in
the present study, it responded the most to both calcium/
vitamin D and calcium/vitamin D + CB6Pro treatments, with
reductions of 23 and 26%, respectively. The expression of
bALP starts after cessation of cell proliferation of osteo-
blasts and reaches a maximum during matrix maturation,
Fig. 2. Pre- and post-treatment bone mineral density (BMD, g/cm2) at lumbar (A and B) and femoral (C) sites in each subject group
(n = 20) for all sites under investigation. Pre- and post-treatment are indicated by plain and hatched bars, respectively. White,
light grey and darker grey bars represent, respectively, the normal controls, the control osteopenic group treated with calcium/
vitamin D, and the experimental osteopenic group treated with calcium/vitamin D combined with three other bone-related nutri-
ents relevant to collagen matrix. Data are means ± SD. Neck: femur neck; Wards: femur Ward’s triangle; Troch: femur trochanter;
Dia: femur diaphysis. Asterisks indicate significance levels for pre- and post-treatment comparisons for each group: *p<0.05;
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but declines during matrix mineralization [36]. OC is the
most abundant non-collagenous protein in bone produced by
osteoblasts. In women taking estrogen, Hannon et al. [37]
found that OC and bALP start to decrease after 6–8 weeks
of treatment, which is consistent with the theory of coupling
of bone formation to bone resorption. In the present study,
the halt in bone loss evidenced by densitometry and
biochemistry (PTH reduction) in osteopenic women whose
treatment aimed at modifying both components of bone
(matrix and minerals) was coupled with a reduction in both
markers of bone formation. Biochemical markers of bone
resorption (fDpd and type I collagen helical peptide) were
weak predictors of bone changes in this study, probably
because the calcium/vitamin D supplement reduced bone
turnover rate and truncated the ranges of these two markers.
The 9% reduction in type I collagen helical peptide observed
after one-year calcium/vitamin D + CB6Pro treatment was
noteworthy, although not significant. First, this assay has
been shown to be one of the most sensitive indicators of
resorption to show the antiresorptive effect of estrogens and
bisphosphonates [38]. Furthermore, helical peptide has a
morphological significance. Constituting the major structural
part of the collagen molecule, a greater urinary excretion
of this peptide, as occurs when there is osteoporosis, can
only result from a degradation of collagen. This protein
degenerative process, in line with bone resorption, outlines
the contribution of bone matrix.
No bone loss was detectable at the spine and femur bone
sites in the calcium/vitamin D + CB6Pro-treated osteopenic
group as compared to the other two groups who did exhibit
some bone loss. This finding is especially noteworthy
considering that osteopenia was more severe in this group,
non only based on T-score (WHO criteria), but also on more
recent absolute reference values used by bone researchers,
i.e. <0.9 g/cm2 for lumbar spine and <0.795 g/cm2 for femur
neck, respectively [39–40]. It appears that the CB6Pro pre-
paration enhanced the calcium/vitamin D supplement effi-
cacy in building new bone and this could explain the success
of their combination in halting bone loss. Reduced osteo-
clastic activity was confirmed biochemically by the reduc-
tion of PTH. The observed decrease in 1,25(OH)2D3
obtained with the calcium/vitamin D supplement, together
with an unchanged serum phosphate level, as found in the
present study in agreement with Elders et al.’s study [41],
could be interpreted to mean that PTH is the most important
mediator. The bone-sparing effect observed with the calcium/
vitamin D-CB6Pro treatment is interesting because it was
achieved not so much through a reduction in osteoclastic
activity, suggesting that a beneficial effect at the level of
bone matrix also took place. This improvement in architec-
ture and structural stability of the bone tissue, attributed to
the role of vitamins C, B6 and proline in collagen, could
never have been obtained with a mineral supplement. A
bone matrix of better quality would be more efficient at
retaining minerals and preventing further bone loss. Several
recent animal studies have highlighted this newly recog-
nized issue of bone matrix quality.
The ability of the calcium/vitamin D + CB6Pro treatment
as compared to calcium/vitamin D supplement alone to
stabilize bone mass and prevent further bone loss was the
most worthy finding of this study. BMD was then main-
tained in this group, at all bone sites of interest, after one
year when three major nutrients essential to bone matrix
structure were prescribed in pharmacological doses, together
with a 1000 mg calcium supplement. BMD at the femur
neck in the control osteopenic group, receiving the calcium/
vitamin D supplement alone, significantly increased, but
decreased at five lumbar sites. Morton et al. [ 17] also
showed improvement at the femur neck when using calcium
but only when it was combined to vitamin C supplement
(745 mg in average). According to Riis et al. [42], calcium
supplement may have a minor effect on the loss of cortical
bone, but it had no effect on trabecular bone. The placebo
group in the present study lost 2% bone minerals after one
year at one lumbar site. According to Alekel et al. [43], the
loss at the vertebral sites in perimenopausal bone is 2–3%
per year.
Other studies, mostly carried out on postmenopausal
women, have also shown the partial effect of calcium
supplement in preventing bone loss. In Agnusdei et al.’s [10]
double-blind, placebo-controlled study for prevention of
postmenopausal spinal bone loss, only patients treated with
ipriflavone, a new nonsteroidal agent, a synthetic derivative
of naturally occurring isoflavones (a group of phytoestro-
gens), had a significant increase in skeletal mineral content
compared with women who received oral calcium supple-
ment or placebo. In a meta-analysis, it was concluded that
the published literature until 1990 shows a consistent posi-
tive effect of calcium supplement in postmenopausal women
at all sites, except the lumbar spine [44]. Few years later,
Riggs et al. [8] and Storm et al. [9] found significant BMD
improvement in postmenopausal women at both lumbar and
appendicular sites using 1600 mg or 1000 mg, respectively.
The effect of calcium on BMD is still a controversial subject,
varying according to duration of study, anatomic site, age,
baseline dietary level and BMD values, but independently of
estrogen status [41]. The literature on osteopenic women of
middle-age is scarce.
In conclusion, the question of the efficacy of calcium
supplementation to treat lumbar bone loss should be
considered still open. In the present one-year follow-up
study, lumbar bone loss persisted in osteopenic patients
treated with conventional calcium/vitamin D supplement. In
contrast, further bone loss was prevented at all lumbar and
femoral sites in the osteopenic group of women treated with
three nutrients involved in the cell-mediated remodeling ofP.G. Masse et al.
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bone through its collagenous matrix, in addition to calcium/
vitamin D. The good safety and tolerability profile of both
calcium/vitamin D and CB6Pro makes their combination a
promising option for the treatment of mid-age osteopenia as
an early preventive measure against osteoporosis. Large
well-controlled investigations are needed to confirm the
efficacy of this new approach. Its long-term effect should
also be tested to verify if the positive results observed in the
present placebo-control study with CB6Pro supplementation
in conjunction with a calcium/vitamin D supplement, after
one-year treatment, can be sustained over a longer period of
time.
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